Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MS Awareness Week

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Research Partnership

Biogen Idec building

NICE backtracks on Biogen’s multiple sclerosis drug Zinbryta

Recommends the treatment after new cost effectiveness and a discount provided

- PMLiVE

Novartis talks the talk with new MS digital tools

Presents real world terms in online dictionary and Chrome Extension

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

Roche Basel Switzerland

FDA delays verdict on Roche’s MS drug Ocrevus

Additional manufacturing data postpones US verdict until 28 March 2017

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

Novartis Gehry Building

New drugs help Novartis shrug off Gleevec competition

However, warns of lesser profits this year as firm looks to boost promotion of Entresto

Roche Basel Switzerland

Roche’s MS drug Ocrevus awarded priority review by FDA

Comes as Swiss company files the therapy with the FDA and EMA

Merck licences MS brain training programme

Strikes deal with HAPPYneuron to bolster its MSdialog platform for Rebif

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links